SPY—QQQ719.02+0.09%BTC/USD—DIA—GLD—TLT79.52+0.08%
Benzinga
Updated: Oct 19, 2026

Jeffrey Walch's Stock Ratings

Bernstein Analyst

Jeffrey Walch is an analyst at Bernstein. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends.

Overall Average Return

-2.93%

Smart Score

33.6%

Overall Average Return Percentile

30th

Number of Ratings

10
Buy NowGet Alert
08/25/2026SMMTBuy Now
Summit Therapeutics
$15.36-22.51%$9.8 → $11.9UpgradeUnderperform → Market PerformGet Alert
08/21/2026RVMDBuy Now
Revolution Medicines
$181.36-1.3%$151 → $179MaintainsMarket PerformGet Alert
06/24/2026NUVLBuy Now
Nuvalent
——$172 → $124DowngradeOutperform → Market PerformGet Alert
05/22/2026NBIXBuy Now
Neurocrine Biosciences
$136.9861.34% → $221Initiates → OutperformGet Alert
05/22/2026INCYBuy Now
Incyte
$113.36-12.67% → $99Initiates → Market PerformGet Alert
05/22/2026JAZZBuy Now
Jazz Pharmaceuticals
$208.439.87% → $229Initiates → Market PerformGet Alert
05/22/2026RVMDBuy Now
Revolution Medicines
$181.36-16.74% → $151Initiates → Market PerformGet Alert
05/22/2026BNTXBuy Now
BioNTech
$89.217.61% → $96Initiates → Market PerformGet Alert
05/22/2026SMMTBuy Now
Summit Therapeutics
$15.36-49.86% → $7.7Initiates → UnderperformGet Alert
05/22/2026NUVLBuy Now
Nuvalent
—— → $189Initiates → OutperformGet Alert
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved